Literature DB >> 17920286

Incidence, risk factors, and prognosis of postoperative hyperbilirubinemia after heart transplantation.

Ron-Bin Hsu1, Fang-Yue Lin, Robert J Chen, Nai-Kuan Chou, Wen-Je Ko, Nai-Hsin Chi, Shoei-Shen Wang, Shu-Hsun Chu.   

Abstract

OBJECTIVE: The clinical significance of postoperative hyperbilirubinemia after heart transplantation has not been reported. Here, we sought to evaluate the incidence, risk factors, and prognosis of postoperative hyperbilirubinemia after heart transplantation.
METHODS: Between 1987 and 2005, 256 consecutive patients undergoing heart transplantation were studied prospectively. Postoperative hyperbilirubinemia was defined as occurrence of a serum total bilirubin concentration of more than 3mg/dl in any measurement during the postoperative period. Logistic regression was done to identify possible risk factors for postoperative hyperbilirubinemia and hospital mortality.
RESULTS: Overall incidence of postoperative hyperbilirubinemia was 57%. Among all patients, there were 35 hospital deaths (14%). In patients with postoperative hyperbilirubinemia, the mean onset time was 2.4+/-4.4 days after transplantation and the mean peak serum total bilirubin was 10.1+/-10.4 mg/dl. Development of postoperative hyperbilirubinemia was associated with a higher mortality (21% vs 5%, P<0.001 by Fisher's exact test). The onset time of postoperative hyperbilirubinemia, the peak serum total bilirubin level, and the time at which the peak bilirubin level was reached were associated with hospital mortality. Old donor age, valvular heart disease, high right atrial pressure, use of mechanical ventilation before transplant, and ascites at transplant were the significant risk factors for postoperative hyperbilirubinemia.
CONCLUSIONS: Postoperative hyperbilirubinemia is common in patients undergoing heart transplantation and is associated with high hospital mortality. Patients with valvular heart disease, high preoperative right atrial pressure, and ascites at transplant, who then receive an old donor heart, are at greater risk for development of postoperative hyperbilirubinemia.

Entities:  

Mesh:

Year:  2007        PMID: 17920286     DOI: 10.1016/j.ejcts.2007.09.013

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Post Cardiopulmonary Bypass Changes in Liver Function: Comment on "J Cardiovasc Thorac Res 2015;7:49-54".

Authors:  Mehrdad Asgeri
Journal:  J Cardiovasc Thorac Res       Date:  2015

Review 2.  The prognostic significance of postoperative hyperbilirubinemia in cardiac surgery: systematic review and meta-analysis.

Authors:  Dev Raveendran; Jahan C Penny-Dimri; Reny Segal; Julian A Smith; Mark Plummer; Zhengyang Liu; Luke A Perry
Journal:  J Cardiothorac Surg       Date:  2022-05-26       Impact factor: 1.522

3.  Rare causes of hyperbilirubinemia after lung transplantation: our experience at a single center.

Authors:  Su Hwan Lee; Moo Suk Park; Jin Gu Lee; Joo Han Song; Kyung Soo Chung; Ji Ye Jung; Eun Young Kim; Young Sam Kim; Se Kyu Kim; Joon Chang; Hyo Chae Paik; Song Yee Kim
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

4.  Characteristics and outcomes of Stanford type A aortic dissection patients with severe post-operation hyperbilirubinemia: a retrospective cohort study.

Authors:  Xiaolan Chen; Ming Bai; Lijuan Zhao; Yangping Li; Yan Yu; Wei Zhang; Feng Ma; Shiren Sun; Xiangmei Chen
Journal:  J Cardiothorac Surg       Date:  2020-07-28       Impact factor: 1.637

5.  Time to peak bilirubin concentration and advanced AKI were associated with increased mortality in rheumatic heart valve replacement surgery patients with severe postoperative hyperbilirubinemia: a retrospective cohort study.

Authors:  Xiaolan Chen; Ming Bai; Lijuan Zhao; Yan Yu; Yuan Yue; Shiren Sun; Xiangmei Chen
Journal:  BMC Cardiovasc Disord       Date:  2021-01-06       Impact factor: 2.298

6.  Severe postoperative hyperbilirubinemia in congenital heart disease.

Authors:  Xiaolan Chen; Ming Bai; Shiren Sun; Xiangmei Chen
Journal:  Open Med (Wars)       Date:  2021-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.